Core Insights - Exponent, Inc. reported strong financial performance in Q3 2025, with double-digit net revenue growth driven by diversified service offerings across various sectors [2][4]. Financial Results - Total revenues for Q3 2025 increased by 8% to $147.1 million, while revenues before reimbursements rose by 10% to $137.1 million compared to Q3 2024 [4]. - Net income for Q3 2025 was $28.0 million, or $0.55 per diluted share, up from $26.0 million, or $0.50 per diluted share in Q3 2024 [5]. - EBITDA for Q3 2025 increased to $38.8 million, representing 28.3% of revenues before reimbursements, compared to $35.8 million, or 28.6% in Q3 2024 [6]. Year-to-Date Performance - For the first three quarters of 2025, total revenues and revenues before reimbursements both increased by 3% to $434.6 million and $407.4 million, respectively, compared to the same period in 2024 [7]. - Net income for the first three quarters of 2025 decreased to $81.2 million, or $1.58 per diluted share, down from $85.4 million, or $1.66 per diluted share in the same period of 2024 [8]. - EBITDA for the first three quarters of 2025 decreased to $113.4 million, or 27.8% of revenues before reimbursements, compared to $115.8 million, or 29.3% in the same period of 2024 [9]. Business Segments - The engineering and other scientific segment accounted for 84% of revenues before reimbursements in Q3 2025, with a 10% increase in revenues compared to the prior year [12]. - The environmental and health segment represented 16% of revenues before reimbursements, with a 9% increase in Q3 2025 driven by regulatory consulting in the chemicals industry [13]. Business Outlook - The company is maintaining its revenue guidance and raising margin guidance for the full year, indicating confidence in long-term growth despite challenges posed by a return to a 52-week fiscal year [14]. - Exponent is strategically increasing headcount to support growth and is optimistic about new engagements and talent influx [14].